|Guideline/Statement||Summary of CT Recommendations|
|2013 ACC/AHA risk assessment guideline||If, after quantitative risk assessment using traditional risk factors, a risk-based treatment decision is uncertain, CAC score may be considered to inform treatment decision making. Class IIb, Level of Evidence: B (7).|
|2016 European guidelines on CVD prevention||CAC scoring may be considered as a risk modifier in CV risk assessment. Class IIb, Level of Evidence: B (8).|
|2017 expert consensus from the Society of Cardiovascular Computed Tomography||It is appropriate to perform CAC testing in the context of shared decision making for asymptomatic individuals without clinical ASCVD who are 40–75 years of age in the 5%–20% ten-year ASCVD risk group and selectively in the <5% ASCVD risk group, such as those with a family history of premature CAD (91).|
|2018 U.S. Preventive Services Task Force draft guideline on nontraditional risk factors||In asymptomatic adults, the current evidence is insufficient to assess the balance of benefits and harms of adding CAC score to traditional risk assessment for CVD prevention. Class I (123).|
ACC = American College of Cardiology; AHA = American Heart Association; ASCVD = atherosclerotic cardiovascular disease; other abbreviations as in Table 1.